Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LSL Pharma Group Inc V.LSL

Alternate Symbol(s):  LPGIF | V.LSL.DB

Healthcare Biotechnology
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specialized in the development, manufacturing and commercialization of sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms. It specializes in the manufacturing and marketing of natural health products (NHPs). The Company manufactures a range of NHPs in liquid... see more

Recent & Breaking News (TSXV:LSL)

LSL PHARMA GROUP EXPANDS ITS ACTIVITIES BY AQUIRING DERMOLAB PHARMA AND ANNOUNCES THE CLOSING OF A CONCURRENT DEBT FINANCING

Canada NewsWire 7 days ago

LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES

Canada NewsWire November 25, 2024

LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP

Canada NewsWire November 6, 2024

LSL PHARMA GROUP ANNOUNCES THE FIRST INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

Canada NewsWire October 24, 2024

LSL PHARMA GROUP ANNOUNCES CHANGE OF AUDITORS AND GRANT OF OPTIONS

Canada NewsWire September 26, 2024

LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024

Canada NewsWire August 26, 2024

LSL Pharma Group Announces Closing of Second and Final Tranche of Private Placement and Closing of Units for Debt

GlobeNewswire July 15, 2024

LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders

GlobeNewswire June 28, 2024

LSL Pharma Group Secures $1.5 Million as the First Closing of Its Non-Brokered Private Placement

GlobeNewswire June 27, 2024

LSL Pharma Group Completes the Acquisition of Virage Santé

GlobeNewswire June 18, 2024

LSL Pharma Group Announces Engagement of Red Cloud Securities

GlobeNewswire June 11, 2024

LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $4.5 Million

GlobeNewswire June 5, 2024

LSL Pharma Group Reports Record Revenues and Margins for the First Quarter 2024

GlobeNewswire May 30, 2024

LSL Pharma Group Announces Listing of Convertible Redeemable Debentures on the TSXV

GlobeNewswire May 22, 2024

LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor

GlobeNewswire May 6, 2024

LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights

GlobeNewswire April 30, 2024

LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units

GlobeNewswire April 24, 2024

LSL Pharma Group Announces the Addition of New Members to Its Board of Directors

GlobeNewswire April 23, 2024

LSL Pharma Group Announces the Upsizing of Its Private Placement From $3.5 Million to $7.5 Million

GlobeNewswire April 11, 2024

LSL Pharma Group Announces its Participation in the "2024 Bloom Burton & Co. Healthcare Investor Conference "

GlobeNewswire April 9, 2024